On the 24th, Hanmi Pharmaceutical announced that it will present six preclinical research results on three obesity treatments at the upcoming European Association for the Study of Diabetes next month.
Hanmi Pharmaceutical will present studies related to the obesity treatments HM17321, HM15275, and HM101460. HM17321 is an obesity treatment that reduces fat while increasing muscle mass. The research results applicable to obese primates will be presented at the conference.
HM15275 is an obesity treatment that optimizes the actions of three receptors: glucagon-like peptide (GLP)-1, glucose-dependent insulinotropic peptide (GIP), and glucagon. The company states that it has a weight loss effect that surpasses that of gastric surgery. HM101460 is an oral obesity treatment.
The European Association for the Study of Diabetes will be held from the 15th to the 19th of next month in Vienna, Austria. Hanmi Pharmaceutical noted, "This treatment goes beyond simple weight loss and can preserve muscle, which will help patients with sarcopenia or reduced exercise ability and the elderly."